• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Taligen Therapeutics

edit

Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company’s lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen’s founders have validated as an important amplification loop in the inflammation process.

Recent Milestones

edit

• 
  Taligen Therapeutics — has been acquired by Alexion Pharmaceuticals Inc., a Connecticut therapeutics firm, for $111 million in an up front cash payment (1/31/11)
  Posted 1/31/11 at 6:47am via masshightech.com
• 
  Taligen Therapeutics was acquired by Alexion Pharmaceuticals for $111M. (1/31/11)
  Posted 1/31/11 at 8:59pm via masshightech.com
• 
  Taligen Therapeutics received $10M in Series B funding. (8/23/10)
  Posted 8/23/10 at 8:03am via dowjones.com
• 
  Taligen Therapeutics received $65M in Series B funding. (1/1/08)
  Posted 6/21/09 at 11:35pm via taligentherapeutics.com
• 
  Taligen Therapeutics received $3.75M in Series A funding. (8/1/05)
  Posted 8/31/10 at 3:36am via taligentherapeutics.com
• 
  Taligen Therapeutics added Abbie Celniker as CEO.
  Posted 6/21/09 at 11:35pm
• 
  Taligen Therapeutics added Woodruff Emlen as President and co-founder.
  Posted 6/21/09 at 11:35pm

Videos

Screenshots

edit

Above: Home
Uploaded: 6/22/09

Sources

1. Taligen Therapeutics acquired for $111M (masshightech.com) [edit]
2. Taligen Therapeutics Announces Successful Achievement of Series A Milestone (taligentherapeutics.com) [edit]
3. Taligen Therapeutics Secures Series B Financing (taligentherapeutics.com) [edit]
4. Taligen Set To Enter Clinic After Securing $10M Series B Tranche (fis.dowjones.com) [edit]
Taligen Therapeutics acquired for $111M (masshightech.com) [edit]